Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

13 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Screening Serology GOAL Trial B-cell Lymphoma NCT02499003

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 8 Elementos de dados, 1 Idioma
Grupo de itens: Serology Viral
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Visit: Screening. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results - Hematology Weeks 4, 5 and 6

- 25/07/2018 - 1 Formulário, 2 Grupos de itens, 7 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology finding
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Follow-UP

- 25/07/2018 - 1 Formulário, 3 Grupos de itens, 32 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Week 7

- 25/07/2018 - 1 Formulário, 3 Grupos de itens, 28 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Week 13

- 25/07/2018 - 1 Formulário, 3 Grupos de itens, 28 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results Hematology/Chemistry Week 3

- 25/07/2018 - 1 Formulário, 3 Grupos de itens, 28 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology finding, Chemistry
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Results - Baseline

- 13/07/2018 - 1 Formulário, 5 Grupos de itens, 37 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology finding, Chemistry, Pregnancy Test, Beta-2 Microglobulin (Serum)
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Reference Ranges

- 10/07/2018 - 1 Formulário, 5 Grupos de itens, 15 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Hematology, Other Parameters, Chemistry, Thyroid Parameters
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Complete this form for each clinical lab for which data are reported on case report forms. For data reported from outside institutions, please obtain the reference ranges and lab certification documentation. Use same Lab ID number on all laboratory forms. The form only needs to be completed once for each lab unless ranges or units change.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Laboratory Identification Log

- 10/07/2018 - 1 Formulário, 1 Grupo de itens, 4 Elementos de dados, 1 Idioma
Grupo de itens: Laboratory Identification
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Laboratory GOAL Trial B-cell Lymphoma NCT02499003

- 04/01/2018 - 1 Formulário, 3 Grupos de itens, 123 Elementos de dados, 1 Idioma
Grupos de itens: Admininstrative data, Laboratory Hematology, Laboratory Blood chemistry
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Pregnancy test GOAL Trial B-cell Lymphoma NCT02499003

- 04/01/2018 - 1 Formulário, 1 Grupo de itens, 4 Elementos de dados, 1 Idioma
Grupo de itens: Pregnancy Test
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Laboratory GOAL Trial B-cell Lymphoma NCT02499003

- 01/01/2018 - 1 Formulário, 4 Grupos de itens, 150 Elementos de dados, 1 Idioma
Grupos de itens: Admininstrative data, Laboratory Hematology, Laboratory Blood chemistry, Laboratory Parameters
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial